Ποια είναι η τιμή για Paratek Pharmaceuticals, Inc. (PRTK)

Η τιμή για Paratek Pharmaceuticals, Inc. (PRTK) είναι $2.23

Ποια είναι η κεφαλαιοποίηση αγοράς για Paratek Pharmaceuticals, Inc. (PRTK)

Η κεφαλαιοποίηση αγοράς για Paratek Pharmaceuticals, Inc. (PRTK) είναι $101.43M

Paratek Pharmaceuticals, Inc. (PRTK) Ιστορικό Τιμών

Paratek Pharmaceuticals, Inc., a biopharmaceutical firm headquartered in Boston, Massachusetts, and founded in 1996, is actively engaged in the commercialization of its products. The company's core mission involves the creation and market introduction of crucial medical treatments for severe illnesses or major public health crises, intended for civilian, governmental, and military applications. Their flagship therapeutic offerings include NUZYRA and SEYSARA. NUZYRA is a comprehensive, once-daily antibiotic, available in both oral and intravenous forms, prescribed for adult patients battling community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens. SEYSARA, a medication derived from the tetracycline class, is specifically formulated to address moderate to severe cases of acne vulgaris. Beyond its internal development, Paratek maintains several strategic alliances. This includes licensing and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc. The company also holds a license from Tufts University, enabling the development and commercialization of solutions for bacterial or microbial diseases. Furthermore, a significant contract with the Biomedical Advanced Research and Development Authority (BARDA) is in place to advance NUZYRA for treating pulmonary anthrax. Additionally, Paratek has a licensing agreement with Tetraphase Pharmaceuticals, Inc. to oversee the development, import, and sale of the XERAVATM product, utilized for complicated intra-abdominal infections of bacterial origin.

Έτος	Απόδοση
2023	15.55%
2022	-56.40%
2021	-33.93%
2020	89.38%
2019	-41.53%
2018	-66.49%
2017	28.53%
2016	-22.56%
2015	-38.43%
2014	20.92%
2013	-31.41%
2012	-31.93%
2011	2.31%
2010	2.53%
2009	0.00%

Έτος

Απόδοση

2023

15.55%

2022

-56.40%

2021

-33.93%

2020

89.38%

2019

-41.53%

2018

-66.49%

2017

28.53%

2016

-22.56%

2015

-38.43%

2014

20.92%

2013

-31.41%

2012

-31.93%

2011

2.31%

2010

2.53%

2009

0.00%

Εταιρεία	Τιμή μετοχής	Μεταβολή 1Έτ%	Χώρα
Vertex Pharmaceuticals Incorporated VRTX.US	$547.71	38.62%	US
Argenx SE ARGX.US	$1.04K	58.06%	NL
Moderna, Inc. MRNA.US	$145.75	437.43%	US
CSL Limited CSL.AX	$118.70	-15.60%	AU
Lonza Group AG LONN.SW	$770.19	8.98%	CH

Εταιρεία

Τιμή μετοχής

Μεταβολή 1Έτ%

Χώρα